Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.

Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Rouanne M, Marlow R, Bajrami I, Cardeñosa ML, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, Marabelle A, Tutt AN, Soria JC, Lord CJ, Postel-Vinay S.

J Clin Invest. 2018 Dec 27. pii: 123319. doi: 10.1172/JCI123319. [Epub ahead of print]

2.

Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.

Xiao JJ, Nowak D, Ramlau R, Tomaszewska-Kiecana M, Wysocki PJ, Isaacson J, Beltman J, Nash E, Kaczanowski R, Arold G, Watkins S.

Clin Transl Sci. 2018 Nov 14. doi: 10.1111/cts.12600. [Epub ahead of print]

PMID:
30427584
3.

The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.

Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P.

Crit Rev Oncol Hematol. 2018 Nov;131:83-89. doi: 10.1016/j.critrevonc.2018.08.011. Epub 2018 Sep 3. Review.

PMID:
30293710
4.
5.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.

Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z.

6.
7.

Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.

Motea EA, Fattah FJ, Xiao L, Girard L, Rommel A, Morales JC, Patidar P, Zhou Y, Porter A, Xie Y, Minna JD, Boothman DA.

Clin Cancer Res. 2018 Dec 15;24(24):6459-6470. doi: 10.1158/1078-0432.CCR-17-1118. Epub 2018 Aug 14.

PMID:
30108102
8.

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.

Sulai NH, Tan AR.

Clin Adv Hematol Oncol. 2018 Jul;16(7):491-501. Review.

PMID:
30067621
9.

The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.

Chen Y, Du H.

Biomed Pharmacother. 2018 Mar;99:552-560. doi: 10.1016/j.biopha.2018.01.094. Epub 2018 Feb 20. Review.

PMID:
29895102
10.

The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.

Domchek SM.

Clin Adv Hematol Oncol. 2018 May;16(5):330-332. No abstract available.

PMID:
29851928
11.

Detection of PARP-1 activity based on hyperbranched-poly (ADP-ribose) polymers responsive current in artificial nanochannels.

Liu Y, Fan J, Yang H, Xu E, Wei W, Zhang Y, Liu S.

Biosens Bioelectron. 2018 Aug 15;113:136-141. doi: 10.1016/j.bios.2018.05.005. Epub 2018 May 4.

PMID:
29754052
12.

Rucaparib: a new treatment option for ovarian cancer.

Sabatucci I, Maltese G, Lepori S, Tripodi E, Bogani G, Lorusso D.

Expert Opin Pharmacother. 2018 May;19(7):765-771. doi: 10.1080/14656566.2018.1464557. Epub 2018 Apr 19.

PMID:
29672168
13.

Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.

Musella A, Bardhi E, Marchetti C, Vertechy L, Santangelo G, Sassu C, Tomao F, Rech F, D'Amelio R, Monti M, Palaia I, Muzii L, Benedetti Panici P.

Cancer Treat Rev. 2018 May;66:7-14. doi: 10.1016/j.ctrv.2018.03.004. Epub 2018 Mar 23. Review.

PMID:
29605737
14.

PARP inhibitors for homologous recombination-deficient prostate cancer.

Christenson ES, Antonarakis ES.

Expert Opin Emerg Drugs. 2018 Jun;23(2):123-133. doi: 10.1080/14728214.2018.1459563. Epub 2018 Apr 4. Review.

15.

The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.

Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D.

Gynecol Oncol. 2018 Jun;149(3):575-584. doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20.

PMID:
29567272
16.

Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.

Spatari C, Li W, Schinkel AH, Ragno G, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Apr 15;1083:204-208. doi: 10.1016/j.jchromb.2018.03.014. Epub 2018 Mar 9.

17.

Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition.

Fang P, Madden JA, Neums L, Moulder RK, Forrest ML, Chien J.

Mol Cancer Res. 2018 Jun;16(6):961-973. doi: 10.1158/1541-7786.MCR-17-0607. Epub 2018 Mar 15.

PMID:
29545475
18.

PARP Inhibitors in Ovarian Cancer.

Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, Valabrega G.

Recent Pat Anticancer Drug Discov. 2018;13(4):392-410. doi: 10.2174/1574892813666180305165256. Review.

PMID:
29512470
19.

Design, synthesis and anticancer activities evaluation of novel 5H-dibenzo[b,e]azepine-6,11-dione derivatives containing 1,3,4-oxadiazole units.

He X, Li XY, Liang JW, Cao C, Li S, Zhang TJ, Meng FH.

Bioorg Med Chem Lett. 2018 Mar 1;28(5):847-852. doi: 10.1016/j.bmcl.2018.02.008. Epub 2018 Feb 8.

PMID:
29456106
20.

PARP1-siRNA suppresses human prostate cancer cell growth and progression.

Lai Y, Kong Z, Zeng T, Xu S, Duan X, Li S, Cai C, Zhao Z, Wu W.

Oncol Rep. 2018 Apr;39(4):1901-1909. doi: 10.3892/or.2018.6238. Epub 2018 Jan 26.

PMID:
29393407

Supplemental Content

Loading ...
Support Center